Carcinoma, Squamous Cell Clinical Trial
Official title:
A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.
The purpose of this study is to determine whether afamelanotide (CUV1647) is effective in
reducing the number of actinic keratoses and squamous cell carcinomas developing in immune
compromised organ transplant recipients, who are at particularly high risk, over a 24 month
test period.
The number of lesions formed on the head, hands and forarms will be monitored over this 24
month test period.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02743832 -
A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
|
N/A | |
| Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
| Completed |
NCT00389727 -
Simultaneous Integrated Boost (SIB)- IMRT
|
Phase 2 | |
| Recruiting |
NCT02328391 -
STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE
|
N/A | |
| Completed |
NCT00875381 -
Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin
|
N/A | |
| Completed |
NCT00534950 -
Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck
|
N/A | |
| Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
| Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT01362127 -
Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia
|
Phase 2 | |
| Completed |
NCT00240682 -
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
|
Phase 2 | |
| Terminated |
NCT02254044 -
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
|
Phase 1 | |
| Completed |
NCT00313027 -
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation
|
N/A | |
| Completed |
NCT00539630 -
TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN
|
Phase 3 | |
| Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
| Not yet recruiting |
NCT06094829 -
Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
|
||
| Recruiting |
NCT04481256 -
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
|
N/A | |
| Recruiting |
NCT06295809 -
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT02664935 -
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT02438995 -
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 |